Hosted on MSN
Data show teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback